InSite licenses ophthalmic drug delivery device:
This article was originally published in Clinica
Executive Summary
InSite Vision has obtained an exclusive worldwide licence to the University of Rochester's device for the controlled delivery of ophthalmic drugs to the posterior chamber of the eye. The patented device has a needle with an adjustable collar, attached to a curved neck, which is inserted above the eyeball and beneath the upper eyelid. InSite also has an eyedrop-based delivery system, DuraSite, and is developing new diagnostic and therapeutic approaches under its glaucoma genetics programme.